The dopamine transporter/cocaine receptor (DAT) is the site at which cocaine exerts rewarding/reinforcing effects. Recent cloning of the DAT cDNA allows structure/function relationships of the DAT to be sought by mutating selected residues and examining influences on cocaine analog recognition and dopamine transport. Mutations preferentially affecting one of these processes provide novel direct evidence for the possibility that anticocaine medications could differentially impact one of these processes but not the other. Because of work defining the amino acids important for catecholamine recognition by catecholamine receptors, and data suggesting that polar regions of cocaine are important for transporter recognition of this molecule, polar residues in transmembrane segments were mutated. Knowledge about cysteine residues would help to understand the molecule's structure. Substitution of aspartate 79 dramatically reduced uptake of dopamine and MPP+ and the mutants' affinity for CFT without affecting B(max). Replacement of the serines in the 7th hydrophobic region reduced dopamine and MPP+ uptake, while sparing CFT binding. Changing serines in the 8th hydrophobic region has no effects. These results demonstrate that aspartate and serine residues lying within putative transmembrane regions are crucial for DAT function, and provide the first identification of residues differentially important for cocaine binding and for dopamine uptake. Elucidating the structures of the putative extracellular domains is also important. Substitution for the cysteines in the DAT second hydrophobic putative extracellular domain selectively and interestingly decreases the function of mutant transporters, conversely, substitution for either of two other cystines had no significant influence. Features of transporter secondary structure are thus important for transporter function.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000076-01
Application #
3838584
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Uchiumi, Osamu; Kasahara, Yoshiyuki; Fukui, Asami et al. (2013) Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine. Neuropharmacology 64:348-56
Seeman, Philip; Hall, Frank Scott; Uhl, George (2007) Increased dopamine D2High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse 61:573-6
Fukushima, Setsu; Shen, Haowei; Hata, Harumi et al. (2007) Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology (Berl) 193:55-62
Yamamoto, Hideko; Kamegaya, Etsuko; Hagino, Yoko et al. (2007) Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture. Neurochem Int 51:237-44
Uhl, George (2007) Premature poking: impulsivity, cocaine and dopamine. Nat Med 13:413-4
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu et al. (2007) Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol 572:120-8
Dar, Dalit E; Metzger, Thomas G; Vandenbergh, David J et al. (2006) Dopamine uptake and cocaine binding mechanisms: the involvement of charged amino acids from the transmembrane domains of the human dopamine transporter. Eur J Pharmacol 538:43-7
Yamashita, Motoyasu; Fukushima, Setsu; Shen, Hao-wei et al. (2006) Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 31:2132-9
Drgon, Tomas; Lin, Zhicheng; Wang, Gene-Jack et al. (2006) Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol 26:875-89
Dar, Dalit E; Mayo, Cheryl; Uhl, George R (2005) The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands. Biochem Pharmacol 70:461-9

Showing the most recent 10 out of 21 publications